In another setback in the lucrative lung cancer market, Bristol-Myers Squibb (BMY) said Thursday that it is withdrawing its application with the Food and Drug Administration to use its cancer immunotherapy blockbuster, Opdivo, in combination with Yervoy, a second Bristol drug, for some patients with previously untreated non-small cell lung cancer.

The news comes as Bristol is announcing strong fourth-quarter earnings, with sales up 10 percent from last year to $6 billion and earnings per share excluding items of 94 cents, 10 cents ahead of the expectations of analysts polled by FirstCall. Sales of Opdivo increased 33 percent to $1.8 billion in the quarter, helping to drive the strong quarter. The company’s announcement also comes just weeks after it said it would purchase rival cancer drug maker Celgene for $74 billion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy